American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Vaxart, Inc. (VXRT)

$0.41 -7.03% OTC: VXRT · 15-min delayed

SOUTH SAN FRANCISCO, California
Public · OTC: VXRT
Founded 2004

Visit website Follow

$237.3MRevenue · FY2025

$16.3MNet income

VXRTOTC

2004Founded

About Vaxart, Inc.

VAXART INC

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Founded: 2004
Type: Public · OTC: VXRT
Headquarters: SOUTH SAN FRANCISCO, California
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: VXRT OTC
SEC CIK: 72444
EIN: 591212264
SIC: 2836 Biological Products, (No Diagnostic Substances)

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Vaxart, Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/vaxart-inc/"><img src="https://americancompanies.com/badge/vaxart-inc.svg" alt="Vaxart, Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow Vaxart, Inc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $237.3M
Net income: $16.3M
Total assets: $186.1M

Source: SEC EDGAR · updated Jun 7, 2026

OTC: VXRT

$0.41 -7.03%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$0.33 $0.80

52-week range

Open: —
Day range: –
Prev close: —
Volume: —

Vaxart, Inc. (VXRT) Stock Price

Profitable — net income of $16.3M in FY2025.
Trading 49% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Vaxart, Inc..

Write a review

Newsroom

News about Vaxart, Inc.

Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements GlobeNewswire Inc. · 2026-07-01 · positive Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY GlobeNewswire Inc. · 2026-06-26 · positive 3 Stocks Under $5 With Strong Analyst Upside Potential Investing.com · 2026-02-24 · positive Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program Benzinga · 2025-11-05 · positive Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program Benzinga · 2025-11-05 · positive Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025 GlobeNewswire Inc. · 2025-10-08 · positive

News & sentiment via Polygon.io

FAQ

Vaxart, Inc.: frequently asked questions

Is Vaxart, Inc. an American company?

Vaxart, Inc. is a US-based company headquartered in South San Francisco, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Vaxart, Inc. headquartered?

Vaxart, Inc. is headquartered in South San Francisco, California, United States.

Is Vaxart, Inc. publicly traded?

Yes — Vaxart, Inc. is a publicly traded company. Its stock trades under the ticker symbol VXRT on the OTC.

What does Vaxart, Inc. do?

Vaxart, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

When was Vaxart, Inc. founded?

Vaxart, Inc. was founded in 2004.

Explore